Lupin Limited

LUPIN

INE326A01037

Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).

Sector

Pharmaceuticals

Calendar

11:30am - Q4 2024 Earnings Call

More about the company

Income Statement Evolution

More financial data

Ratings for Lupin Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1,680 INR

Average target price

1,516 INR

Spread / Average Target

-9.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LUPIN LIMITED	+21.73%	9.17B
ELI LILLY AND COMPANY	+31.52%	690B
NOVO NORDISK A/S	+25.03%	546B
JOHNSON & JOHNSON	-5.21%	358B
MERCK & CO., INC.	+17.02%	323B
ABBVIE INC.	+5.01%	287B
ASTRAZENECA PLC	+14.15%	235B
NOVARTIS AG	+5.43%	199B
ROCHE HOLDING AG	-9.90%	195B
AMGEN INC.	+3.98%	161B

Other Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:16:56 07/05/2024 BST			5-day change	1st Jan Change
1,611 ^INR	-4.12%		-2.12%	+21.73%

06:52am	Lupin's Consolidated Profit Climbs in Fiscal Q4; Shares Dip 4%	MT
05-06	Indian drugmaker Lupin misses quarterly profit estimates as costs rise	RE

Lupin's Consolidated Profit Climbs in Fiscal Q4; Shares Dip 4%	05:52am	MT
Indian drugmaker Lupin misses quarterly profit estimates as costs rise	05-06	RE
Lupin Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-06	CI
Lupin Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-06	CI
Lupin Limited Receives an Order from Office of the State Tax Inspector, Jurisdiction: Ghatak 56: Range - 14: Division - 6: Gujarat	04-30	CI
Lupin Receives US FDA Inspection Report for Aurangabad, India Manufacturing Facility	04-24	MT
INDIA STOCKS-Indian shares rise tracking Asia rebound; drop in HDFC Bank caps gains	04-22	RE
Lupin Launches Mirabegron Extended-Release Tablets in US	04-22	MT
Lupin Limited Announces Launch of Mirabegron Extended-Release Tablets, 25 Mg, in the United States, After Having Received an Approval from the United States Food and Drug Administration	04-20	CI
US FDA Clears Lupin's API Plant in Gujarat, India, Following GMP Inspection	04-12	MT
Lupin Launches Generic Version of Oracea (Doxycycline Capsules) in US	04-10	MT
Lupin Launches Generic Drug for Inflammatory Lesions of Rosacea in US	04-09	MT
Lupin Limited Announces the Launch of First Generic Version of Oracea® (Doxycycline Capsules, 40 Mg), in the United States	04-09	CI
Indian Equities Close with Marginal Loss on Wednesday as Traders Scale Down Hopes on US Rate Cuts	04-03	MT
Lupin Names Chief Quality Officer	04-03	MT
Lupin Limited Announces Change in Management	04-03	CI
Lupin to Transfer Trade Generics Business to Subsidiary Lupin Life Sciences	03-25	MT
Lupin Limited Receives an Order from the Additional Commissioner of State Tax, Central Division, Patna	03-21	CI
Indian Equities Start Week in Black, Aided by Major Auto and Metal Firms	03-18	MT
Lupin Names Chief Technical Operations Officer	03-18	MT
Lupin Limited Appoints Christoph Funke as Chief Technical Operations Officer	03-18	CI
Boehringer to cut out-of-pocket costs for inhalers to $35	03-07	RE
India pharma companies develop versions of Wegovy to get in on weight-loss windfall	02-22	RE
Lupin Gets US FDA Nod for Minzoya Tablets	02-16	MT
Lupin Limited Receives Approval from U.S. FDA for Minzoyatm	02-16	CI